Completed PHASE3 INTERVENTIONAL 3-arm NCT00035490

Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators

Sponsor: Forest Laboratories

Interventions Azimilide Dihydrochloride placebo

Updated 7 times since 2017 Last updated: Sep 30, 2011 Started: Sep 30, 2001 Primary completion: Apr 30, 2004 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Arrhythmia and is currently completed. Forest Laboratories leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories

Data source: Forest Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Bad Bevensen, Germany , Bad Nauheim, Germany , Bad Oeynhausen, Germany , Baltimore, United States , Barcelona, Spain , Bari, Italy , Berlin, Germany , Beverly Hills, United States , Bonn, Germany and 118 more locations